11-cis-retinal

11-cis-ret·i·nal

(ret'i-năl),
The isomer of retinaldehyde that can combine with an opsin to form either iodopsin or rhodopsin; it is formed from 11-trans-retinal by retinal isomerase.
Synonym(s): neoretinal b

11-cis-ret·i·nal

(sis'ret'i-năl)
The isomer of retinaldehyde that can combine with opsin to form rhodopsin; it is formed from 11-trans-retinal by retinal isomerase.
References in periodicals archive ?
We thank Autum Pairett for tissue preparation and transcriptome analyses, Rosalie Crouch (Storm Eye Institute, Medical University of South Carolina) and the National Eye Institute for supplying 11-cis-retinal, and Belinda Chang for providing the expression vector p1D4-hrGFP II.
In past, it was observed that the rate-limited supply of 11-cis-retinal from the retina pigment epithelium (RPE) to the outer side of the photoreceptors has direct effects on the rhodopsin cycle [27].
Vancouver-based QLT is developing a synthetic retinoid programme to treat retinal diseases caused by gene mutations that interfere with the availability of 11-cis-retinal.
11-cis-retinal is a key biochemical component of the visual retinoid cycle, the deficiency of which is associated with certain inherited or age-related retinal diseases, including Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
Mutations in the genes for retinal pigment epithelium protein 65 (RPE65) and lecithin:retinol acyltransferase (LRAT) result in an inadequate production of 11-cis-retinal and occur in approximately 10% of patients with LCA, and to a lesser extent in Retinitis Pigmentosa (RP), another inherited retinal dystrophy.
QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, and is under investigation for the treatment of LCA and RP.
The compound is expected to slow the regeneration of 11-cis-retinal in the retina, and has been demonstrated to have beneficial effect in several preclinical models of retinal degeneration by stopping the accumulation of retinoid-related toxic byproducts including A2E.
This patent, which is expiring on 11 May 2027, covers various methods of use of QLT091001 in the treatment of diseases associated with an endogenous 11-cis-retinal deficiency, which is associated with certain inherited or age-related retinal diseases, including Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal and is currently under investigation for the treatment of LCA and RP, stated the company.
The basis for using synthetic retinoids as replacement therapy for conditions where genetic defects result in deficiency of 11-cis-retinal is founded on experiments in mouse genetic models, including those developed in the laboratory of Dr.
QLT said that QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, and is under investigation for the treatment of LCA and RP.